Artiva Biotherapeutics, Inc.
ARTV
$2.88
$0.113.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -131.00% | -176.21% | -127.62% | -- | -- |
| Total Depreciation and Amortization | 7.26% | 8.66% | 7.28% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.36% | 21.84% | 12.75% | -- | -- |
| Change in Net Operating Assets | 92.12% | 103.84% | 98.85% | -- | -- |
| Cash from Operations | -37.64% | -23.85% | -16.03% | -- | -- |
| Capital Expenditure | -33.08% | 19.73% | 80.29% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,165.88% | -822.34% | -427.45% | -- | -- |
| Cash from Investing | -1,360.99% | -739.26% | -363.77% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -75.64% | -- | -- | -- | -- |
| Issuance of Common Stock | 757,509.09% | 1,666,860.00% | 1,665,480.00% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -110.90% | -116.60% | -117.15% | -- | -- |
| Cash from Financing | 620.06% | 565.76% | 565.11% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.32% | 53.94% | 72.93% | -- | -- |